# Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

> **NCT04314843** · PHASE1 · TERMINATED · sponsor: **Kite, A Gilead Company** · enrollment: 6 (actual)

## Conditions studied

- Relapsed/Refractory Large B-cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Lenzilumab
- **BIOLOGICAL:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT04314843
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-26
- **Primary completion:** 2021-03-16
- **Final completion:** 2022-07-27
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Development program terminated and the decision was not due to any safety concerns.
- **Last updated:** 2024-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314843, "Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04314843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*